Titer on Chip™
InDevR has developed a deep understanding of the vaccine industry through relationships built around our innovative approach to solving analytical bottlenecks in both upstream and downstream vaccine development. Our Virus Counter® technology for rapid quantification of whole virus is now being sold worldwide by ViroCyt LLC. Currently, with support from the National Institute of Allergy and Infectious Diseases, we are developing a new protein analysis platform (Titer on Chip™) that will revolutionize protein quantification for vaccine and biotherapeutic developers. This new product is expected to launch in 2014 – so stay tuned!
In collaboration with the Influenza Division of the Centers for Disease Control and Prevention, we are also developing a new influenza genotyping tool to significantly expand surveillance of emerging influenza viruses. Feel free to contact us if you are interested in flu genotyping or diagnostics.
Watch this page for more information about what’s coming from InDevR.